Edwards Lifesciences Corp (EW)
Sector: Healthcare
Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Country: United States
Exchange: NYSE
Market cap: $50.87B
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Latest financial period: June 30, 2026
Filed with the SEC: August 4, 2026
Estimated earnings date: October 29, 2026
Profit #256 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 82.5% | 84.7% | 85.5% | 87.7% |
Growth #146 of 1484 companies
Payout #322 of 1484 companies
Safety #485 of 1484 companies
Price #1098 of 1484 companies
